hypertension - renin inhibitor - diabetic patients clinical trials results meta-analysis

<h1> <a href="TM7-106-renin inhibitor -hypertension" > <strong>hypertension</strong> - renin inhibitor </a> - diabetic patients trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t9500.htm"> AVOID, 2008 </a> <br> NCT00097955 </td> <td> aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months<br>  <i>versus</i> <br> placebo </td> <td> patients with hypertension and type 2 diabetes with nephropathy </td> <td> follow-up 6 months<br> n=301/298<br> Parallel groups<br> double blind <br> 15 countries </td> </tr> </table> <h2>References</h2> <p> <b>AVOID, 2008 : </b> Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NKAliskiren combined with losartan in type 2 diabetes and nephropathy. <i>N Engl J Med 2008;358:2433-46</i> [PMID 18525041] </p>